☆ 4.7 Article

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial

LANCET INFECTIOUS DISEASES (2023)

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Explore over 38,000 international journals covering a vast array of academic fields.

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now